· Molly Burich, Director of Public Policy, Boehringer Ingelheim   · Surya Singh, President, Singh Healthcare Advisors, LLC  Moderated Panel Discussion  Meredyth Andrus, Attorney, Health Care Division, Bureau of Competition, FTC Does the designation of interchangeability still have value in the US? [read post]